1. Azorin JM, Simon N. Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder. Drugs 2019; 79: 1657–1677.
2.
Bahji A, Ermacora D, Stephenson C, Hawken ER, Vázquez G. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis. J Affect Disord 2020; 269: 154–84.
3.
Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: a major unsolved challenge. Int J Bipolar Disord 2020; 8: 1.
4.
Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry 2010; 18: 143–57.
5.
Brignardello-Petersen R, Rochwerg B, Guyatt GH. What is a network meta-analysis and how can we use it to inform clinical practice? Pol Arch Med Wewn 2014; 124: 659–660.
6.
Brown ES, Khaleghi N, Van Enkevort E, Ivleva E, Nakamu ra A, Holmes T, et al. A pilot study of brexpiprazole for bi polar depression. J Affect Disord 2019; 249: 315–18.
7.
Calabrese JR, Durgam S, Satlin A, Vanover KE, Davis RE, Chen R et al. Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. Am J Psychiatry 2021; 178: 1098–1106.
8.
Cha DS, Luo X, Ahmed J, Becirovic L, Cha RH, McIntyre RS. Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder. Expert Rev Neurother 2019; 19: 777–783.
9.
Diaz AP, Fernandes BS, Quevedo J, Sanches M, Soares JC. Treat ment-resistant bipolar depression: concepts and challenges for novel interventions. Braz J Psychiatry 2022; 44: 178–186.
10.
Dudek D, Siwek M, Zielińska D, Jaeschke R, Rybakowski J. Diagnostic conversions from major depressive disorder into bipolar disorder in an outpatient setting: Results of a ret rospective chart review. J Affect Disord 2013; 144: 112–115.
11.
Earley W, Burgess MV, Rekeda L, Dickinson R, Szatmari B, Németh G et al. Cariprazine Treatment of Bipolar Depres sion: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. Am J Psychiatry 2019; 176: 439–448.
12.
Earley WR, Burgess MV, Khan B, Rekeda L, Suppes T, To hen M, et al. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. Bipolar Disord 2020; 22: 372–384.
13.
Elsayed OH, Ercis M, Pahwa M, Singh B. Treatment-Resist ant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions. Neuropsychiatr Dis Treat 2022; 18: 2927–2943.
14.
Haggarty SJ, Karmacharya R, Perlis RH. Advances toward precision medicine for bipolar disorder: mechanisms & mo lecules. Mol Psychiatry 2021; 26: 168–185.
15.
Ishigooka J, Kato T, Miyajima M, Watabe K, Masuda T, Hagi K et al. Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study. J Affect Disord 2021; 281: 160–167.
16.
Jaeschke RR, Sowa-Kućma M, Pańczyszyn-Trzewik P, Misz tak P, Styczeń K, Datka W. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacol Rep 2016; 68: 748–755.
17.
Jain R, McIntyre RS, Cutler AJ, Earley WR, Nguyen HB, Adams JL et al. Efficacy of cariprazine in patients with bi polar depression and higher or lower levels of baseline anxi ety: a pooled post hoc analysis. Int Clin Psychopharmacol 2024; 39: 82–92.
18.
Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H. Safety assess ment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. J Affect Disord 2024; 346: 223–229.
19.
Kadakia A, Dembek C, Heller V, Singh R, Uyei J, Hagi K, et al. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry 2021; 21: 249.
20.
Kato T. Current understanding of bipolar disorder: Toward integration of biological basis and treatment strategies. Psy chiatry Clin Neurosci 2019; 73: 526–540.
21.
Keramatian K, Chakrabarty T, Saraf G, Yatham LN. New Developments in the Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder: a Systematic Review of Re cent Randomized Controlled Trials. Curr Psychiatry Rep 2021; 23: 39.
22.
Krupa AJ, Wojtasik-Bakalarz K, Siwek M. Vortioxetine – pharmacological properties and use in mood disorders. The current state of knowledge. Psychiatr Pol 2023; 57: 1109–1126.
23.
Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tam minga CA et al. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biol Psychiatry 2016; 79: 952–961.
24.
Loebel A, Siu C, Rajagopalan K, Pikalov A, Cucchiaro J, Ket ter TA. Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. J Affect Disord 2015; 186: 376–382.
25.
Malhi GS, Chengappa KNR. Why ‘mood stabilizer’ needs stability: Polar views on its utility. Bipolar Disord 2017; 19: 414–416.
26.
McIntyre RS, Calabrese JR. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin 2019; 35: 1993–2005.
27.
McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lur asidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry 2015; 76: 398–405.
28.
McIntyre RS, Durgam S, Huo J, Kozauer SG, Stahl SM. The Efficacy of Lumateperone in Patients With Bipolar De pression With Mixed Features. J Clin Psychiatry 2023; 84: 22m1473.
29.
McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM. Caripra zine efficacy in bipolar I depression with and without con current manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr 2020; 25: 502–510.
30.
Miller JN, Black DW. Bipolar Disorder and Suicide: a Review. Curr Psychiatry Rep 2020; 22: 6.
31.
Post RM. The impact of bipolar depression. J Clin Psychiatry 2005; 66 Suppl 5: 5–10.
32.
Rybakowski JK. Meaningful aspects of the term ‘mood sta bilizer’. Bipolar Disord 2018; 20: 391–392.
33.
Rybakowski JK. Mood Stabilizers of First and Second Gen eration. Brain Sci 2023; 13.
34.
Siwek M, Gorostowicz A. Lurasidone in Therapy of Treat ment-resistant Ultra-rapid Cycling Bipolar Disorder: Case Report. Clin Psychopharmacol Neurosci 2021; 19: 568–571.
35.
Siwek M, Wojtasik-Bakalarz K, Krupa AJ, Chrobak AA. Brex piprazole – Pharmacologic Properties and Use in Schizophre nia and Mood Disorders. Brain Sci 2023; 13.
36.
Smith DJ, Ghaemi N. Is underdiagnosis the main pitfall when diagnosing bipolar disorder? Yes. BMJ 2010; 340: c854.
37.
Snyder GL, Vanover KE, Zhu H, Miller DB, O’callaghan JP, Tomesch J et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl) 2015; 232: 605–621.
38.
Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Jaesch ke RR, Sendek K, Styczeń K et al. Vortioxetine: A review of the pharmacology and clinical profile of the novel antide pressant. Pharmacol Rep 2017; 69: 595–601.
39.
Stahl SM. Mechanism of action of cariprazine. CNS Spectr 2016; 21: 123–127.
40.
Stahl SM 2021a. Targeting Dopamine and Serotonin Receptors for Psychosis, Mood, and Beyond: So-Called “Antipsychotics”. W: Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Stahl SM, Cambridge Uni versity Press, Cambridge – New York – Port Melbourne – New Delhi – Singapore 2021; New York – Port Melbourne – New Delhi – Singapore: Cambridge University Press; 158–242.
41.
Stahl SM 2021b. Links between Receptor Binding Properties of Drugs Used to Treat Psychosis and Other Therapeutic Ac tions and Side Effects. W: Stahl’s Essential Psychopharmaco logy: Neuroscientific Basis and Practical Applications. Stahl SM, Cambridge University Press, Cambridge – New York – Port Melbourne – New Delhi – Singapore 2021; 195–200.
42.
Stahl SM 2021c. Brexpiprazole. W: Stahl’s Essential Psycho pharmacology: Neuroscientific Basis and Practical Applic ations. Stahl SM, Cambridge University Press, Cambridge – New York – Port Melbourne – New Delhi – Singapore 2021; 239–240.
43.
Stahl SM 2021d. Lumateperone. W: Stahl’s Essential Psy chopharmacology: Neuroscientific Basis and Practical Appli cations. Stahl SM, Cambridge University Press, Cambridge – New York – Port Melbourne – New Delhi – Singapore 2021; 237–239.
44.
Stahl SM 2021e. Prescriber’s Guide: Stahl’s Essential Psy chopharmacology, Cambridge University Press. Kindle Edition.
45.
Stahl SM 2021f. Stahl’s Essential Psychopharmacology: Neu roscientific Basis and Practical Applications, Cambridge – New York – Port Melbourne – New Delhi – Singapore, Cam bridge University Press.
46.
Stahl SM, Laredo S, Morrissette DA. Cariprazine as a treat ment across the bipolar I spectrum from depression to ma nia: mechanism of action and review of clinical data. Ther Adv Psychopharmacol 2020; 10: 204.512.5320905752.
47.
Suppes T, Durgam S, Kozauer SG, Chen R, Lakkis HD, Davis RE et al. Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-con trolled clinical trial. Bipolar Disord 2023; 25: 478–488.
48.
Suppes T, Kelly DI, Perla JM. Challenges in the management of bipolar depression. J Clin Psychiatry 2005; 66 Suppl 5: 11–16.
49.
Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone ad junctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retro spective enrolment cohorts. J Psychiatr Res 2016; 78: 86–93.
50.
Swartz HA, Tasosa JT. A New Option for Treating Bipolar I Depression. Am J Psychiatry 2016; 173: 211–212.
51.
Thase ME. Bipolar depression: issues in diagnosis and treat ment. Harv Rev Psychiatry 2005; 13: 257–271.
52.
Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and safety of adjunctive brexpi prazole 2 mg in major depressive disorder: a phase 3, ran domized, placebo-controlled study in patients with inade quate response to antidepressants. J Clin Psychiatry 2015; 76: 1224–1231.
53.
Tocco M, Mao Y. Efficacy and Safety of Adding Lurasidone to Ongoing Therapy With Lithium or Valproate for the Treat ment of an Acute Bipolar Depressive Episode: A Post Hoc Analysis of 2 Placebo-Controlled Trials. J Clin Psychophar macol 2024; 44: 345–352.
54.
Vieta E, McIntyre RS, Yu J, Aronin LC, Kramer K, Nguyen HB. Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients ex periencing mood episodes: Post hoc analysis of pooled ran domized controlled trial data. J Affect Disord 2024; 366: 136–145.
55.
Wichniak A, Samochowiec J, Szulc A, Dudek D, Heitzman J, Janas-Kozik M, et al. Stanowisko grupy roboczej Polskiego Towarzystwa Psychiatrycznego na temat stosowania częścio wych agonistów receptorów dopaminowych D2/D3 w lecze niu zaburzeń psychicznych. Psychiatr Pol 2021a; 55: 941–966.
56.
Wichniak A, Siwek M, Rymaszewska J, Janas-Kozik M, Wo lańczyk T, Bieńkowski P et al. Stanowisko grupy roboczej Polskiego Towarzystwa Psychiatrycznego na temat stoso wania częściowych agonistów receptorów dopaminowych D2/D3 w populacjach szczególnych. Psychiatr Pol 2021b; 55: 967–987.
57.
Wojtasik-Bakalarz K, Siwek M. New antipsychotic medica tion. Farm Psychiatr Neurol 2023; 39: 19–38.
58.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of pa tients with bipolar disorder. Bipolar Disord 2018; 20: 97–170.
59.
Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W. Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications. Prim Care Companion CNS Disord 2020; 22: 20m02611.
